Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2022 | Recent advances in mHSPC: 177Lu-PSMA-617, PROpel and biomarker-directed strategies

Joe O’Sullivan, MD, Queen’s University, Belfast, UK, describes the ongoing studies in the field of metastatic hormone-sensitive prostate cancer (mHSPC), including the PSMAddition trial (NCT04720157), a Phase III study comparing treatment with 177Lu-PSMA-617 plus standard of care versus standard of care alone in patients with mHSPC, as well as the STAMPEDE trial (NCT00268476) where 177Lu-PSMA-617 may be added to a treatment arm. In addition, Dr O’Sullivan touches on precision medicine, highlighting biomarker-driven studies which may determine which patients benefit most from chemotherapy as well as findings from the PROpel study (NCT03732820) which aimed to determine whether all comers may benefit from the addition of a PARP inhibitor to abiraterone. This interview took place at the European Association of Urology (EAU) Meeting 2022.


Prof. O’Sullivan reports the following conflicts of interest:
Personal fees for Advisory Board and Speaker’s bureau from: AAA/Novartis, Astellas, Bayer, Janssen, Sanofi